CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

191 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BKRASRS61764370PredictiveSupportsResistanceEpithelial Ovarian CancerCarboplatin,PaclitaxelRatner et al., 2012
DKRASMutationPredictiveSupportsSensitivity/ResponseOvarian CancerDecitabineStewart et al., 2015
BKRASRS61764370PredictiveSupportsResistanceHead And Neck Squamous Cell CarcinomaCisplatinChung et al., 2014
BKRASExon 2 MutationPredictiveDoes Not SupportResistancePancreatic CarcinomaErlotinibBoeck et al., 2013
BKRASExon 2 MutationPrognosticSupportsPoor OutcomePancreatic CarcinomaBoeck et al., 2013
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximab,DasatinibDunn et al., 2011
BKRASG12VPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaRenaud et al., 2015
BKRASG12/G13PredictiveDoes Not SupportSensitivity/ResponsePancreatic AdenocarcinomaTrametinibInfante et al., 2014
BKRASMutationPredictiveDoes Not SupportResistanceLung Non-small Cell CarcinomaMEK Inhibitor RO4987655Zimmer et al., 2014
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,TeprotumumabEbi et al., 2011
DKRASMutationPredictiveSupportsSensitivity/ResponseCancerG-573,MEK Inhibitor GDC-0623Hatzivassiliou et al., 2013
DKRASG12CPredictiveSupportsSensitivity/ResponseCancerEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853Patricelli et al., 2016
BKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabSchirripa et al., 2015
DKRASMutationPredictiveSupportsSensitivity/ResponseCancerAZD5438Costa-Cabral et al., 2016
BKRASExon 2 MutationPredictiveSupportsResistanceColorectal CancerEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorAzuara et al., 2016
BKRASG12DPrognosticSupportsBetter OutcomeColorectal CancerModest et al., 2012
BKRASG12CPredictiveSupportsResistanceColorectal CancerErlotinib,GefitinibFiala et al., 2013
BKRASG12CPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaIhle et al., 2012
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung AdenocarcinomaSalirasibRiely et al., 2011
BKRASG12DPrognosticSupportsPoor OutcomeMalignant Exocrine Pancreas NeoplasmRachakonda et al., 2013
BKRASMutationPrognosticSupportsPoor OutcomePseudomyxoma PeritoneiPietrantonio et al., 2016
DKRASMutationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
BKRASG12DPrognosticSupportsPoor OutcomePancreatic Ductal CarcinomaBournet et al., 2016
CKRASG12DPredictiveSupportsSensitivity/ResponseColorectal CancerTherapeutic Tumor Infiltrating LymphocytesTran et al., 2016
DKRASG12VPredictiveSupportsSensitivity/ResponseColorectal CancerDactolisib,SelumetinibMigliardi et al., 2012
BKRASG12/G13PredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CKRASG13DPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
CKRASG12DPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
DKRASA146TPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
BKRASG12DPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
DKRASA146VPredictiveSupportsSensitivity/ResponseColorectal CancerDactolisib,SelumetinibMigliardi et al., 2012
DKRASG12DPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
BKRASG12VPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
CKRASA146PPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabLoupakis et al., 2009
BKRASG12/G13PrognosticDoes Not SupportPoor OutcomeColorectal CancerAmado et al., 2008
CKRASG12CPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
BKRASExon 2 MutationPrognosticDoes Not SupportPoor OutcomeColorectal CancerKato et al., 2007
BKRASMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinib,GefitinibLudovini et al., 2011
DKRASA146TPredictiveSupportsResistanceColorectal CancerCetuximabJanakiraman et al., 2010
BKRASMutationPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaBrugger et al., 2011
CKRASG12VPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
BKRASA146TPredictiveSupportsResistanceColorectal CancerCetuximab,FOLFOX-4 RegimenKaczirek et al., 2015
CKRASQ61HPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
CKRASQ61LPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
CKRASQ61RPredictiveSupportsResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
CKRASQ61KPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
BKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BKRASMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinibBrugger et al., 2011
BKRASA146PredictiveDoes Not SupportResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
DKRASG12DPredictiveSupportsResistanceOvarian CancerCetuximabSato et al., 2012
Page 2 of 4
PreviousNext